Cargando…

Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting

BACKGROUND AND OBJECTIVES: Treatment for individuals receiving medication for opioid use disorder (MOUD) should follow an informed patient‐centered approach. To better support patient autonomy in the decision‐making process, clinicians should be aware of patient preferences and be prepared to educat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mannelli, Paolo, Douaihy, Antoine B., Akerman, Sarah C., Legedza, Anna, Fratantonio, James, Zavod, Abigail, Sullivan, Maria A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304146/ https://www.ncbi.nlm.nih.gov/pubmed/35137481 http://dx.doi.org/10.1111/ajad.13264

Ejemplares similares

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
por: Comer, Sandra D., et al.
Publicado: (2020)

Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018
por: Jain, Priya, et al.
Publicado: (2020)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019)

Comment on “Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence”
por: Silverman, Bernard, et al.
Publicado: (2018)

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
por: Kunøe, Nikolaj, et al.
Publicado: (2016)

Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report
por: Szczesniak, Laura M., et al.
Publicado: (2020)

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic
por: Nguyen, Thuy, et al.
Publicado: (2022)

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use
por: Xu, Kevin Y., et al.
Publicado: (2022)

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
por: Cook, R. R., et al.
Publicado: (2023)

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
por: Nunes, Edward V., et al.
Publicado: (2015)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone
por: Karlsson, Ann Tarja, et al.
Publicado: (2021)

Medication Treatment for Opioid Use Disorders:: A Brief Overview with Comments on Extended Release Naltrexone
por: Woody, George
Publicado: (2017)

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
por: Marciuch, Anne, et al.
Publicado: (2023)

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
por: Earley, Paul H., et al.
Publicado: (2017)

The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
por: Parchinski, Kaley, et al.
Publicado: (2023)

Extended-release monthly buprenorphine injection
por: Cuperfain, Ari B., et al.
Publicado: (2023)

Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia
por: Ruger, Jennifer Prah, et al.
Publicado: (2012)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Epidemiologic and Molecular Pathophysiology of Chronic Opioid Dependence and the Place of Naltrexone Extended-Release Formulations in its Clinical Management
por: Reece, Albert Stuart
Publicado: (2012)

Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone
por: Karlsson, Ann Tarja, et al.
Publicado: (2022)

Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence
por: Li, Xinyi, et al.
Publicado: (2023)

Adapting treatment length to opioid‐dependent individuals’ needs and preferences: a 2‐year follow‐up to a 1‐year study of extended‐release naltrexone
por: Solli, Kristin Klemmetsby, et al.
Publicado: (2021)

Pharmacological enhancement of naltrexone treatment for opioid dependence: a review
por: Mannelli, Paolo, et al.
Publicado: (2011)

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
por: Larance, Briony, et al.
Publicado: (2020)

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020)

Whose mu fared better? The effect of extended-release naltrexone (XR-NTX) on treatment outcomes for opioid and alcohol users
por: Crèvecoeur-MacPhail, Desirée A
Publicado: (2015)

Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis
por: Hoffman, Kim A., et al.
Publicado: (2021)

Subcutaneous Extended-Release Buprenorphine Use in Pregnancy
por: Towers, Craig V., et al.
Publicado: (2020)

A Prospective Three-Months Naturalistic Follow-Up Study of Outcomes of Patients with Opioid Dependence Discharged on Buprenorphine or Oral Naltrexone
por: Singh, Virendra Vikram, et al.
Publicado: (2022)

Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence
por: Wang, A-L, et al.
Publicado: (2015)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex – United States, March 2019 – December 2020
por: Cremer, Laura J., et al.
Publicado: (2022)

Naltrexone Implant for Opioid Use Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021)

Co-relationship between sexual dysfunction and high-risk sexual behavior in patients receiving buprenorphine and naltrexone maintenance therapy for opioid dependence
por: Ramdurg, Santosh, et al.
Publicado: (2015)

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
por: Chappuy, Mathieu, et al.
Publicado: (2021)

Injection Site Reaction to Extended-Release Buprenorphine (Sublocade(®)) for Opioid Use Disorder Fourteen Days after Administration
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature
por: Ramsey, Susan E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_uudc1b84v8qn2nthlq3ka39bo1